Abstract
ABSTRACT In the field of regenerative medicine, cartilage tissue regeneration presents a challenge because it is not sufficiently self-healing. Rheumatic diseases like osteoarthritis and rheumatoid arthritis, among various others, contribute to cartilage damage causing pain, inflammation and immobility of joints. In recent years, administration of disease modifying anti-rheumatic drugs (DMARDs) by incorporating them into injectable hydrogels has emerged as a promising approach to cartilage tissue regeneration. DMARDs exhibit anti-inflammatory and immunomodulatory properties which contribute in reduction of inflammation. These characteristics enable them to control inflammatory response, encourage chondrogenesis and thereby facilitate regeneration of cartilage. Pre-clinical and clinical research has been reported for safety and effectiveness where hydrogels containing DMARDs show promising efficacy and safety. Drug concentrations of DMARDs are tailored based on effective concentration, delivery, structural integrity of hydrogels in consideration with pharmacodynamics and physicochemical properties. Ongoing research is evaluating long-term safety and therapeutic potential. Some hydrogel systems are already approved and commercially available, while others are in optimization studies. This review summarizes current landscape of injectable hydrogels containing DMARDs, highlighting their application in cartilage tissue regeneration, encompassing both pre-clinical and clinical research that has evidenced safety and effectiveness and also providing insights into market prospects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
